Carlsmed, Inc. (NASDAQ: CARL), an AI-enabled spine surgery firm, saw its stock soar 6.21% in after-hours trading on Wednesday, marking a significant reversal from its earlier performance during its Nasdaq debut. The company, which had just completed its initial public offering (IPO), raised $100.5 million by selling 6.7 million shares at $15 each, the midpoint of its marketed range.

The stock's after-hours rally comes as a contrast to its earlier performance. During regular trading hours, Carlsmed shares had fallen as much as 6.7% from their IPO price, closing at $14.57, down 2.8% from the offering price. This initial decline was likely due to broader market conditions and investor caution surrounding newly listed companies.

Founded in 2018, Carlsmed is a commercial-stage medical technology company focused on pioneering AI-enabled personalized spine surgery solutions. The successful completion of its IPO, despite the initial stock price decline, demonstrates investor interest in innovative medical technology firms. The after-hours surge may indicate that investors are reassessing the company's potential in the growing field of AI-assisted medical procedures.